65,437 trials
Infantile Colics
Primary: Median Daily Crying Time at the End of the Treatment — 50; 55; 80 minutes
PostPartum Depression
Primary: Structured Clinical Interview for DSM-IV Axis I Disorders — 7.94; 8.20 percentage of participants
Prostate Cancer
Primary: Best Overall PSA Response — 8; 20; 65 percentage of participatns
Asthma
Primary: Mean Growth Rate in Lower-leg Growth, as Determined by Knemometry. — 0.3638; 0.3118 millimeter per week
Seizure · Epilepsy · Cerebral Malaria
Primary: Minutes With Seizure on EEG — 165.2; 464.8 minutes with seizure
Nystagmus
Primary: Change in logMAR Visual Acuity of Each Eye, Measured During Far or Near Viewing — 0; 0.1; 0.2; 0.2 logMAR
Type 2 Diabetes
Primary: Hepatic Steatosis — 6.7; NA; 8.4; 5.9 percentage of liver fat — p=0.03
Hypertension
Primary: 24-hour Average Systolic Blood Pressure — 127; 127; 126; 129 mmHg
Neuroblastoma
Primary: Percentage of Participants That Are Able to Meet Feasibility Parameters. — 100 percentage of participants
Sphincter of Oddi Dysfunction
Primary: Percentage of Participants With Success — 23; 37 percentage of paricipants with success — p=0.01
Acute Liver Failure · Hepatic Encephalopathy
Primary: Survival — 68; 76 Participants — p=0.19
Malignant Glioma
Primary: Change From Baseline in Fatigue at Day 43 — -1; -3 units on a scale — p=0.3
Kidney Disease, Chronic
Primary: Percentage of Participants With an Adverse Event (AE) and a Serious Adverse Event — 3; 0.40 percentage of participants
Colorectal Cancer
Primary: Percentage of Participants Achieving Complete Resection (R0 Resection) — 30.0 percentage of participants
Chronic Pain
Primary: Peak Plasma Concentration of Hydromorphone — 0; 0; 0; NA ng/mL